DNA X, Inc. (Nasdaq: SONM) Announces Full Year 2025 Financial Results and Strategic Transformation
Key Highlights
- Strategic Pivot: Completed acquisition of DNA X cryptocurrency trading platform and divested legacy mobile device business.
- Business Restructuring: Sale of mobile device assets to NEXA Mobility for \$15 million, with immediate payment of \$13.5 million and \$1.5 million due in nine months.
- Rebranding and Leadership Change: Company rebranded to DNA X, Inc.; CEO resigned and Executive Chairman Mike Mulica became acting CEO; Scott Walker, co-founder of DNA Holdings, appointed to board.
- Platform Launch: DNA X.us trading platform launched and now active, focusing on automated cryptocurrency trading strategies.
- Financial Position: Ended 2025 with \$1.3 million in cash and a total assets base of \$43.9 million; reported significant net losses due to transition costs and discontinued operations.
- Outlook: Management expresses confidence in revenue and margin growth as platform promotion begins and product enhancements are introduced.
Detailed Report
Strategic Transformation and Acquisition
DNA X, Inc., formerly Sonim Technologies Inc., has executed a transformative shift in its business model, pivoting from mobile device manufacturing to focus exclusively on decentralized finance (DeFi) and cryptocurrency trading services. The pivotal acquisition of the DNA X cryptocurrency trading platform was finalized in December 2025, following the successful launch of the DNA X.us website in November 2025.
The newly acquired platform is designed to capitalize on price movements between cryptocurrency pairs, enabling clients to automate trading strategies, including recurring and limit orders. This positions DNA X, Inc. at the forefront of automated crypto trading via decentralized exchanges.
Divestiture of Mobile Device Assets
The company completed the sale of its legacy mobile device design and manufacturing business to NEXA Mobility, a private hardware company, on January 23, 2026. The asset sale, valued at \$15 million (subject to working capital adjustments), included an immediate payment of \$13.5 million and a deferred payment of \$1.5 million in nine months. Proceeds from the sale were primarily used to repay debt and obligations, with the remaining cash earmarked for supporting and expanding the DNA X trading platform.
Rebranding and Leadership Changes
Reflecting its new strategic direction, the company rebranded as DNA X, Inc. on January 23, 2026. The NASDAQ ticker symbol SONM remains unchanged, and corporate headquarters continue to be located in San Diego.
Significantly, on January 30, 2026, the Chief Executive Officer and board member resigned. Executive Chairman Mike Mulica assumed the role of acting CEO. Additionally, Scott Walker, co-founder of DNA Holdings (the entity that sold the DNA X platform), joined the board, bringing extensive expertise in cryptocurrency trading.
Financial Performance – 2025
- Revenue: No revenue from continuing operations in Q4 or full-year 2025, as all mobile device revenue was classified as discontinued operations.
- Operating Expenses: General and administrative expenses for continuing operations were \$1.2 million in Q4 and \$5.4 million for the full year, driven by legal and transactional costs related to the acquisition, asset sale, and shareholder votes.
- Cash Position: The company ended the year with \$1.3 million in cash from continuing operations, supplemented by proceeds from the asset sale.
- Net Loss: Net loss from continuing operations was \$7.96 million in 2025, with an additional \$12.7 million loss from discontinued operations, resulting in a total net loss of \$20.66 million for the year. This compares to a net loss of \$33.65 million in 2024.
Balance Sheet Overview (as of December 31, 2025)
- Total Assets: \$43.9 million (up from \$39.7 million in 2024)
- Total Liabilities: \$50.6 million (up from \$45.4 million in 2024)
- Stockholders’ Deficit: \$(8.0) million (worsened from \$(5.7) million in 2024)
- Reverse Stock Split: 1-for-18 reverse split effective October 28, 2025
2026 Outlook and Management Commentary
Management expects to exit the monitoring and testing phase and commence active marketing of the DNA X trading platform in 2026. CFO Clay Crolius expressed optimism for future revenue, gross margin, and profitability growth, citing product enhancements and a wider selection of tradable cryptocurrencies as key drivers.
Acting CEO Mike Mulica emphasized the company’s strategic transition to a high-growth, early-stage industry, noting the substantial opportunities presented by the DeFi and cryptocurrency trading sector.
Risks and Forward-Looking Statements
Shareholders should be aware of several key risks that could materially impact share value:
- The company’s ability to successfully integrate and scale the DNA X trading platform is uncertain, given its early-stage business status and the volatility of cryptocurrency markets.
- Recent divestiture of the legacy business may introduce operational risks and liquidity challenges.
- Ongoing compliance with Nasdaq listing requirements and other regulatory factors remain critical.
- Potential delays or challenges in executing the company’s strategic plans could impact future results.
Further details on risks are included in the company’s filings with the SEC, including its latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Contact Information
For further information, investors can contact Clay Crolius, DNA X, Inc. at [email protected]. More information is also available at https://ir.dna-x.global.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Investors should conduct their own due diligence and consult with a licensed financial advisor before making investment decisions.
View DNA X, Inc. Historical chart here
